Drug sensitivity and sphingolipid metabolism in CLL

Blood

Volumn 120, Issue 19, 2012, Pages 3865-3866

  Jaeger, Ulrich ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; B LYMPHOCYTE RECEPTOR; IBRUTINIB; IDELALISIB; SPHINGOLIPID;

CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DRUG MECHANISM; DRUG SENSITIVITY; LIPID METABOLISM; MOLECULARLY TARGETED THERAPY; NOTE; PRIORITY JOURNAL;

EID: 84868549057     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-455394     Document Type: Note

References (10)

1. Schwamb J, Feldhaus V, Baumann M, et al. B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glycosylation of ceramides. Blood. 2012;120(19): 3978-3985.
2. Furman RR. Prognostic markers and stratification of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:77-81.
3. Hillmen P. Using the biology of chronic lymphocytic leukemia to choose treatment. Hematology Am Soc Hematol Educ Program. 2011;2011:104-109.
4. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101-105.
5. Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as atherapeutic target. Blood. 2012; 120(6):1175-1184.
6. Herishanu Y, Perez-Galan P, LiuDet al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117(2):563-574.
7. Steininger C, Widhopf GF 2nd, Ghia EM, et al. Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen. Blood. 2012;119(10):2293-2301.
8. Furman RR, Byrd JC, Brown JR, et al. CAL-101, an isoform-seleective inhibitor of phosphatidylinositol 3-kinase P110, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116:55.
9. O'Brien S, Burger JA, Blum KA, et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Follow-up of a phase Ib/II study [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118:983.
10. Bilban M, Heintel D, Scharl T, et al. Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression. Leukemia. 2006;20(6):1080-1088. (Pubitemid 43797301)